Growth patterns during the first two years of a child's life may shape pubertal growth and adult height, but have little ...

The research, published in Nature Human Behavior, analyzed MRI scans from over 1,000 children to map how different brain ...

Topline data were announced from a phase 3 trial evaluating somapacitan in children born small for gestational age, with Noonan syndrome, or with idiopathic short stature.

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Syracuse, NY -- Upstate’s pediatric primary care practice is nearly doubling its footprint in Syracuse’s northern suburbs in ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more effective ...

Somapacitan was noninferior to somatropin in improving yearly growth rate in children born SGA, or with NS or ISS. Topline data were announced from a phase 3 trial evaluating somapacitan in pre ...